Does long-term profound inhibition of gastric acid secretion increase the risk of ECL cell-derived tumors in man?

Scandinavian Journal of Gastroenterology

Volumn 51, Issue 7, 2016, Pages 767-773

  Waldum, Helge L ^a,b   Hauso, Øyvind ^a,b   Brenna, Eiliv ^a,b   Qvigstad, Gunnar ^a,b   Fossmark, Reidar ^a,b  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

Author keywords

ECL cell; gastric acid inhibition; gastric cancer; gastric carcinoid; gastrin

Indexed keywords

CHOLECYSTOKININ B RECEPTOR; GASTRIN; HISTAMINE; PROTON PUMP INHIBITOR;

CANCER RISK; CELL HYPERPLASIA; CELL PROLIFERATION; ENTEROCHROMAFFIN LIKE CELL; ENTEROCHROMAFFIN LIKE CELL DERIVED TUMOR; GASTRINOMA; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HISTAMINE RELEASE; HUMAN; HYPERGASTRINEMIA; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; STOMACH ACID SECRETION; STOMACH ADENOCARCINOMA; STOMACH CANCER; STOMACH CARCINOGENESIS; STOMACH CARCINOID; STOMACH CARCINOMA; STOMACH PH; ANIMAL; CHEMICALLY INDUCED; HYPERPLASIA; PATHOLOGY; PHYSIOLOGY; RODENT; SECRETION (PROCESS); STOMACH ACID; STOMACH TUMOR;

ANIMALS; ENTEROCHROMAFFIN-LIKE CELLS; GASTRIC ACID; HUMANS; HYPERPLASIA; PROTON PUMP INHIBITORS; RODENTIA; STOMACH NEOPLASMS;

EID: 84958054641     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2016.1143527     Document Type: Review

References (79)

1. L.Ropielski β-Imidazolyläthylamin und die organänextrakte. β-Imidazolyläthylamin als mächtiger erreger der magendrüsen. Plügers Archiv. 1920;178:214–236.
2. R.Hakanson, B.Lilja, C.Owman Cellular localization of histamine and monoamines in the gastric mucosa of man. Histochemie. 1969;18:74–86.
3. R.Hakanson, G.Bottcher, E.Ekblad,. Histamine in endocrine cells in the stomach. A survey of several species using a panel of histamine antibodies. Histochemistry. 1986;86:5–17.
4. P.Barrett, R.C.Hobbs, P.J.Coates,. Endocrine cells of the human gastrointestinal tract have no proliferative capacity. Histochem J. 1995;27:482–486.
5. B.Ryberg, Y.Tielemans, J.Axelson,. Gastrin stimulates the self-replication rate of enterochromaffinlike cells in the rat stomach. Effects of omeprazole, ranitidine, and gastrin-17 in intact and antrectomized rats. Gastroenterology. 1990;99:935–942.
6. P.L.Peghini, B.Annibale, C.Azzoni,. Effect of chronic hypergastrinemia on human enterochromaffin-like cells: insights from patients with sporadic gastrinomas. Gastroenterology. 2002;123:68–85.
7. L.W.Rogers, R.C.Murphy Gastric carcinoid and gastric carcinoma. Morphologic correlates of survival. Am J Surg Pathol. 1979;3:195–202.
8. E.Wilander, M.El-Salhy, P.Pitkanen Histopathology of gastric carcinoids: a survey of 42 cases. Histopathology. 1984;8:183–193.
9. N.Havu Enterochromaffin-like cell carcinoids of gastric mucosa in rats after life-long inhibition of gastric secretion. Digestion. 1986;35:42–55.
10. D.Poynter, C.R.Pick, R.A.Harcourt,. Association of long lasting unsurmountable histamine H2 blockade and gastric carcinoid tumours in the rat. Gut. 1985;26:1284–1295.
11. H.L.Waldum, A.K.Sandvik, E.Brenna,. Gastrin-histamine sequence in the regulation of gastric acid secretion. Gut. 1991;32:698–701.
12. P.M.Kleveland, H.L.Waldum, H.Larsson Gastric acid secretion in the totally isolated, vascularly perfused rat stomach. A selective muscarinic-1 agent does, whereas gastrin does not, augment maximal histamine-stimulated acid secretion. Scand J Gastroenterol. 1987;22:705–713.
13. J.H.Walsh, C.T.Richardson, J.S.Fordtran pH dependence of acid secretion and gastrin release in normal and ulcer subjects. J Clin Invest. 1975;55:462–468.
14. A.S.Kopin, Y.M.Lee, E.W.McBride,. Expression cloning and characterization of the canine parietal cell gastrin receptor. Proc Natl Acad Sci USA. 1992;89:3605–3609.
15. H.L.Waldum, A.K.Sandvik Gastric functional and trophic receptors for CCK. In: T.Smith, editor. Aspects of synaptic transmission. London: Taylor and Francis Ltd; 1993. p. 157–172.
16. I.Bakke, G.Qvigstad, A.K.Sandvik,. The CCK-2 receptor is located on the ECL cell, but not on the parietal cell. Scand J Gastroenterol. 2001;36:1128–1133.
17. H.Nakata, T.Matsui, M.Ito,. Cloning and characterization of gastrin receptor from ECL carcinoid tumor of Mastomys natalensis. Biochem Biophys Res Commun. 1992;187:1151–1157.
18. A.K.Sandvik, H.L.Waldum, P.M.Kleveland,. Gastrin produces an immediate and dose-dependent histamine release preceding acid secretion in the totally isolated, vascularly perfused rat stomach. Scand J Gastroenterol. 1987;22:803–808.
19. A.J.Blair, 3rd, M.Feldman, C.Barnett,. Detailed comparison of basal and food-stimulated gastric acid secretion rates and serum gastrin concentrations in duodenal ulcer patients and normal subjects. J Clin Invest. 1987;79:582–587.
20. E.Brenna, H.L.Waldum Trophic effect of gastrin on the enterochromaffin like cells of the rat stomach: establishment of a dose response relationship. Gut. 1992;33:1303–1306.
21. S.M.Sjoblom, P.Sipponen, S.L.Karonen Argyrophil cell hyperplasia and carcinoid tumours in oxyntic mucosa of the stomach. Dependence on duration of pernicious anaemia. Eur J Gastroenerol Hepatol. 1991;31:153–157.
22. A.G.Oettle Spontaneous carcinoma of the glandular stomach in Rattus (mastomys) natalensis, an African rodent. Br J Cancer. 1957;11:415–433.
23. J.Soga, K.Tazawa, H.Kanahara,. Some characteristic features of spontaneous argyrophil cell carcinoids in glandular stomach of Praomys (mastomys) natalensis. GANN Monograph. 1969;8:15–26.
24. D.Poynter, S.A.Selway, S.A.Papworth,. Changes in the gastric mucosa of the mouse associated with long lasting unsurmountable histamine H2 blockade. Gut. 1986;27:1338–1346.
25. H.Mattsson, N.Havu, J.Brautigam,. Partial gastric corpectomy results in hypergastrinemia and development of gastric enterochromaffinlike-cell carcinoids in the rat. Gastroenterology. 1991;100:311–319.
26. C.Safholm, N.Havu, H.Forssell,. Effect of 7 years' daily oral administration of omeprazole to beagle dogs. Digestion. 1994;55:139–147.
27. L.Ekman, E.Hansson, N.Havu,. Toxicological studies on omeprazole. Scand J Gastroenterol Suppl. 1985;108:53–69.
28. T.C.Martinsen, S.L.Benestad, T.Moldal,. Inhibitors of gastric acid secretion increase the risk of prion infection in mice. Scand J Gastroenterol. 2011;46:1418–1422.
29. F.Hirayama, S.Takagi, E.Iwao,. Development of poorly differentiated adenocarcinoma and carcinoid due to long-term Helicobacter pylori colonization in Mongolian gerbils. J Gastroenterol. 1999;34:450–454.
30. H.L.Waldum, H.Rorvik, S.Falkmer,. Neuroendocrine (ECL cell) differentiation of spontaneous gastric carcinomas of cotton rats (Sigmodon hispidus). Lab Anim Sci. 1999;49:241–247.
31. T.C.Martinsen, S.Kawase, R.Hakanson,. Spontaneous ECL cell carcinomas in cotton rats: natural course and prevention by a gastrin receptor antagonist. Carcinogenesis. 2003;24:1887–1896.
32. T.C.Wang, C.A.Dangler, D.Chen,. Synergistic interaction between hypergastrinemia and Helicobacter infection in a mouse model of gastric cancer. Gastroenterology. 2000;118:36–47.
33. K.Borch, H.Renvall, G.Liedberg Gastric endocrine cell hyperplasia and carcinoid tumors in pernicious anemia. Gastroenterology. 1985;88:638–648.
34. E.Solcia, C.Capella, R.Fiocca,. Gastric argyrophil carcinoidosis in patients with Zollinger-Ellison syndrome due to type 1 multiple endocrine neoplasia. A newly recognized association. Am J Surg Pathol. 1990;14:503–513.
35. C.Bordi, T.D'Adda, F.P.Pilato,. Carcinoid (ECL cell) tumor of the oxyntic mucosa of the stomach: a hormone-dependent neoplasm? Surgical Pathology. Philiadelphia (PA): Field & Wood; 1988.
36. G.Cadiot, C.Vissuzaine, F.Potet,. Fundic argyrophil carcinoid tumor in a patient with sporadic-type Zollinger-Ellison syndrome. Dig Dis Sci. 1995;40:1275–1278.
37. G.E.Feurle Argyrophil cell hyperplasia and a carcinoid tumour in the stomach of a patient with sporadic Zollinger-Ellison syndrome. Gut. 1994;35:275–277.
38. C.Donow, M.Pipeleers-Marichal, S.Schroder,. Surgical pathology of gastrinoma. Site, size, multicentricity, association with multiple endocrine neoplasia type 1, and malignancy. Cancer. 1991;68:1329–1334.
39. J.A.Norton, P.H.Sugarbaker, J.L.Doppman,. Aggressive resection of metastatic disease in selected patients with malignant gastrinoma. Ann Surg. 1986;203:352–359.
40. O.Calvete, J.Reyes, S.Zuniga,. Exome sequencing identifies ATP4A gene as responsible of an atypical familial type I gastric neuroendocrine tumour. Hum Mol Gen. 2015;24:2914–2922.
41. I.M.Modlin, K.D.Lye, M.Kidd A 50-year analysis of 562 gastric carcinoids: small tumor or larger problem? Am J Gastroenterol. 2004;99:23–32.
42. G.Rindi, O.Luinetti, M.Cornaggia,. Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: a clinicopathologic study. Gastroenterology. 1993;104:994–1006.
43. G.Rindi, C.Azzoni, S.La Rosa,. ECL cell tumor and poorly differentiated endocrine carcinoma of the stomach: prognostic evaluation by pathological analysis. Gastroenterology. 1999;116:532–542.
44. A.Kokkola, S.M.Sjoblom, R.Haapiainen,. The risk of gastric carcinoma and carcinoid tumours in patients with pernicious anaemia. A prospective follow-up study. Scand J Gastroenterol. 1998;33:88–92.
45. G.Qvigstad, S.Falkmer, B.Westre,. Clinical and histopathological tumour progression in ECL cell carcinoids (“ECLomas”). APMIS. 1999;107:1085–1092.
46. H.L.Waldum, E.Brenna, A.K.Sandvik Relationship of ECL cells and gastric neoplasia. Yale J Biol Med. 1998;71:325–335.
47. H.L.Waldum, O.A.Haugen, C.Isaksen,. Are diffuse gastric carcinomas neuroendocrine tumours? (ECL-omas). Eur J Gastroenterol Hepatol. 1991;3:245–249.
48. P.Lauren The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 1965;64:31–49.
49. H.L.Waldum, S.Aase, I.Kvetnoi,. Neuroendocrine differentiation in human gastric carcinoma. Cancer. 1998;83:435–444.
50. G.Qvigstad, A.K.Sandvik, E.Brenna,. Detection of chromogranin A in human gastric adenocarcinomas using a sensitive immunohistochemical technique. Histochem J. 2000;32:551–556.
51. G.Qvigstad, T.Qvigstad, B.Westre,. Neuroendocrine differentiation in gastric adenocarcinomas associated with severe hypergastrinemia and/or pernicious anemia. APMIS. 2002;110:132–139.
52. K.Bakkelund, R.Fossmark, I.Nordrum,. Signet ring cells in gastric carcinomas are derived from neuroendocrine cells. J Histochem Cytochem. 2006;54:615–621.
53. O.Sordal, G.Qvigstad, I.S.Nordrum,. The PAS positive material in gastric cancer cells of signet ring type is not mucin. Exp Mol Pathol. 2014;96:274–278.
54. H.L.Waldum, G.Qvigstad Gastric cancer: the role of neuroendocrine cells. In: Cardinni DC, editor. Research focus on gastric cancer. New York: Novo Science Publishers; 2007. p. 91–102.
55. T.Lind, C.Cederberg, G.Ekenved,. Effect of omeprazole–a gastric proton pump inhibitor–on pentagastrin stimulated acid secretion in man. Gut. 1983;24:270–276.
56. N.Havu, H.Mattsson, L.Ekman,. Enterochromaffin-like cell carcinoids in the rat gastric mucosa following long-term administration of ranitidine. Digestion. 1990;45:189–195.
57. J.T.Smith, C.Gavey, C.U.Nwokolo,. Tolerance during 8 days of high-dose H2-blockade: placebo-controlled studies of 24-hour acidity and gastrin. Aliment Pharmacol Ther. 1990;4 Suppl 1:47–63.
58. H.L.Waldum, J.S.Arnestad, E.Brenna,. Marked increase in gastric acid secretory capacity after omeprazole treatment. Gut. 1996;39:649–653.
59. B.K.Sharma, R.P.Walt, R.E.Pounder,. Optimal dose of oral omeprazole for maximal 24 hour decrease of intragastric acidity. Gut. 1984;25:957–964.
60. N.Vakil Review article: esomeprazole, 40 mg once daily, compared with lansoprazole, 30 mg once daily, in healing and symptom resolution of erosive oesophagitis. Aliment Pharmacol Ther. 2003;17:21–23.
61. J.G.Hatlebakk Review article: gastric acidity–comparison of esomeprazole with other proton pump inhibitors. Aliment Pharmacol Ther. 2003;17:10–15.
62. C.Reimer, B.Sondergaard, L.Hilsted,. Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. Gastroenterology. 2009;137:80–87. 7 e1.
63. A.Niklasson, L.Lindstrom, M.Simren,. Dyspeptic symptom development after discontinuation of a proton pump inhibitor: a double-blind placebo-controlled trial. Am J Gastroenterol. 2010;105:1531–1537.
64. R.Lamberts, W.Creutzfeldt, F.Stockmann,. Long-term omeprazole treatment in man: effects on gastric endocrine cell populations. Digestion. 1988;39:126–135.
65. Y.Haga, T.Nakatsura, Y.Shibata,. Human gastric carcinoid detected during long-term antiulcer therapy of H2 receptor antagonist and proton pump inhibitor. Dig Dis Sci. 1998;43:253–257.
66. F.Cavalcoli, A.Zilli, D.Conte,. Gastric neuorendocrine neoplasms and proton pump inhibitiors (PPI): fact or coincidence. Scand J Gastroenterol. 2015;50:1397–1403.
67. C.S.Jianu, R.Fossmark, T.Viset,. Gastric carcinoids after long-term use of a proton pump inhibitor. Aliment Pharmacol Ther. 2012;36:644–649.
68. C.S.Jianu, O.J.Lange, T.Viset,. Gastric neuroendocrine carcinoma after long-term use of proton pump inhibitor. Scand J Gastroenterol. 2012;47:64–67.
69. E.J.Kuipers Proton pump inhibitors and gastric neoplasia. Gut. 2006;55:1217–1221.
70. R.G.Berlin Omeprazole. Gastrin and gastric endocrine cell data from clinical studies. Dig Dis Sci. 1991;36:129–136.
71. Commitee. A. Omeprazole magnesium tablets. Wilmington (DE): Astra Zeneca; 2000.
72. H.L.Waldum, O.Hauso, O.F.Sordal,. Gastrin may mediate the carcinogenic effect of Helicobacter pylori infection of the stomach. Dig Dis Sci. 2015;60:1522–1527.
73. D.E.Henson, C.Dittus, M.Younes,. Differential trends in the intestinal and diffuse types of gastric carcinoma in the United States, 1973–2000: increase in the signet ring cell type. Arch Pathol Lab Med. 2004;128:765–770.
74. Y.Takinami, H.Yuki, A.Nishida,. YF476 is a new potent and selective gastrin/cholecystokinin-B receptor antagonist in vitro and in vivo. Aliment Pharmacol Ther. 1997;11:113–120.
75. R.Fossmark, O.Sordal, C.S.Jianu,. Treatment of gastric carcinoids type 1 with the gastrin receptor antagonist netazepide (YF476) results in regression of tumours and normalisation of serum chromogranin A. Aliment Pharmacol Ther. 2012;36:1067–1075.
76. P.Karimi, F.Islami, S.Anandasabapathy,. Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention. Cancer Epidemiol Biomarkers Prev. 2014;23:700–713.
77. M.van Blankenstein, A.J.van Vuuren, C.W.Looman,. The prevalence of Helicobacter pylori infection in the Netherlands. Scand J Gastroenterol. 2013;48:794–800.
78. W.F.Anderson, M.C.Camargo, J.F.Fraumeni, Jr,. Age-specific trends in incidence of noncardia gastric cancer in US adults. JAMA. 2010;303:1723–1728.
79. I.L.Holster, M.J.Aarts, E.T.Tjwa,. Trend breaks in incidence of non-cardia gastric cancer in the Netherlands. Cancer Epidemiol. 2014;38:9–15.